Double-Blinded, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of BMS-929075 in Treatment Naive Subjects Infected With Hepatitis C Virus Genotype 1.

Trial Profile

Double-Blinded, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of BMS-929075 in Treatment Naive Subjects Infected With Hepatitis C Virus Genotype 1.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 20 Jun 2013

At a glance

  • Drugs BMS 929075 (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Mar 2012 Planned end date changed from 1 Jan 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.
    • 03 Mar 2012 Planned initiation date changed from 1 Mar 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.
    • 07 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top